🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ICYMI, our latest Annual Report is here: chordoma.org/AnnualReport20… Grateful to our donors, collaborators, and team members for contributing to our most significant year of progress yet — thank you for bringing so much hope to everyone facing chordoma!

As AI models for predicting molecular interactions become more powerful and ubiquitous, there’s a rapidly increasing need for capabilities to test their predictions experimentally. We’re racing to develop those capabilities for the brachyury (TBXT) protein Brachyury (TBXT) to

Drug development for rare cancers is often untenable for business. But by making preclinical research much faster and easier we aim to make repurposing or developing drugs for chordoma feasible and even attractive for companies. Thanks to Brad Loncar for highlighting our work!

In memory of my beloved son Mac, who bravely fought metastatic chordoma for over five years, my family and I, in partnership with the Chordoma Foundation, have established the Moving Ahead for Cures (MAC) Fund. Mac’s enduring hope for finding cures for this rare cancer lives on

We're studying replication stress in chordoma, and have recently identified several therapeutic approaches that exploit this vulnerability. Here are 3 new figures we’ve put on @Figshare to enable others to build on our findings before they’re published. 👇

Inspired by findings from Tanaz Sharifnia & Stuart Schreiber that GPX4 is essential in chordoma, we’ve demonstrated that GPX4 inhibition induces ferroptotic cell death, suggesting ferroptosis susceptibility may be a targetable vulnerability in chordoma. Results now on Figshare.

This is another piece of evidence of how societal and economic burden of COVID, flu and other infections can be substantially reduced ❤️‍🩹💰😊. We must reject the narrative of these as an inevitable part of life. Let's clean the air, like we once learned to clean the water 💪.

Science moves faster when we share. 🔬⚡ That's why as often as we can, we upload data generated by Chordoma Foundation Labs to a public data repository called Figshare, allowing other researchers and companies to build on our results months or even years faster than the norm in research,

💯we need to make rare disease research more feasible. We can’t change the market size for rare diseases but if we reduce the time, cost and risk of research — clinical and preclinical — a wider universe of therapeutic approaches will be financially viable to explore.

This should happen. But we can’t wait until it does. And even with funding there’s the obstacle of novelty being worth more in academia than replicating work of others. This is an area where patient driven labs can shine though. Part of the motivation for Chordoma Foundation Labs.

Super proud of the Chordoma Foundation Labs team and grateful to everyone making their progress possible!

Chordoma's most important target, TBXT (brachyury), has long been considered undruggable. Lots of emerging AI approaches and others purport to unlock progress for such difficult targets. To find out which can succeed we're launching the TBXT Challenge with $500K in prizes. More👇

Sharp analysis of the limitations of how pre-commercial technology research is currently organized and a compelling case for alternatives to unlock more progress. Exactly the thinking that motivated Chordoma Foundation Labs. Excited to see these ideas crystallizing.

Nice story from The ICR about this milestone and the personal motivation of the team behind it: icr.ac.uk/research-and-d…

Our latest Annual Report is here: chordoma.org/annualreport20…. 🎉 As you'll read, advances in the past year are unlocking vast new possibilities for chordoma treatment. We're deeply grateful to everyone who made 2024 our most impactful year yet, and we're excited to continue this

We're happy to share that Pyxis Oncology's Phase 1 trial of PYX-201 (Micvotabart pelidotinaka “MICVO”) has opened to patients with sarcomas, including chordoma: clinicaltrials.gov/study/NCT05720… This opportunity came about in part from a discovery made using tumor tissue from our Biobank,

Forever grateful to this team!

Excited to add this role to the CF team. The aim is to expand the pipeline of therapies in development for chordoma by allowing us to support and collaborate with more investigators and companies, and drive more research on our own through CF Labs and CRO partners.